Skip to main content

Artelo Biosciences, Inc.

ARTL
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001621221

No open-market purchases or sales by Artelo Biosciences, Inc. insiders were filed in the last 90 days; 10 institutions reported holding it in 13F filings for Q2 2026, worth $132.0K in total; no superinvestor holds it.

Q4 2025 vs. Q3 2025

How the institutions holding Artelo Biosciences, Inc. changed between Q3 2025 and Q4 2025.

All holders in Q4 2025All holders in Q3 2025

13F holders of ARTL: Q3 2025 compared with Q4 2025
MeasureQ3 2025Q4 2025Change
Holders910+1
Shares33.0K98.5K+65.5K (+198.1%)
Value$151.7K$120.6K−$31.1K (−20.5%)

New holders (6)

Institutions that held Artelo Biosciences, Inc. at the end of Q4 2025 but not at the end of Q3 2025.

Institutions new to ARTL in Q4 2025
InstitutionSharesValue% of portfolio
Two Sigma Investments, LP20,669$25.2K0.00%
Virtu Financial LLC16,865$21.0K0.00%
Geode Capital Management, LLC11,398$13.9K0.00%
Tower Research Capital LLC (TRC)1,903$2.32K0.00%
Advisor Group Holdings, Inc.1$10.00%
CWM, LLC1$00.00%

Sold out (5)

Institutions that held Artelo Biosciences, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.

Institutions that sold out of ARTL in Q4 2025
InstitutionShares, Q3 2025Value, Q3 2025
DRW Securities, LLC17,185$78.9K
Morgan Stanley1,100$5.05K
Citigroup Inc477$2.19K
FMR LLC30$138
Royal Bank of Canada1$0